Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses

Vaccine

Volumn 25, Issue 32, 2007, Pages 6028-6036

  Kistner, Otfried ^a   Howard, M Keith ^a   Spruth, Martin ^a   Wodal, Walter ^a   Brühl, Peter ^a   Gerencer, Marijan ^a   Crowe, Brian A ^a   Savidis Dacho, Helga ^a   Livey, Ian ^a   Reiter, Manfred ^a   Mayerhofer, Ines ^a   Tauer, Christa ^a   Grillberger, Leopold ^a   Mundt, Wolfgang ^a   Falkner, Falko G ^a   Barrett, P Noel ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

H5N1 whole virus vaccine; Vero cells

Indexed keywords

CROSS REACTING ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; EXPERIMENTAL MODEL; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VACCINE PRODUCTION; VERO CELL; VIROGENESIS; WILD TYPE;

ANIMALS; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; GUINEA PIGS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, INACTIVATED; VERO CELLS;

EID: 34447544007     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.013     Document Type: Article

References (34)

1. Lipatov A.S., Govorkova E.A., Webby R.J., Ozaki H., Peiris M., Guan Y., et al. Influenza: emergence and control. J Virol 78 17 (2004) 8951-8959
2. Palese P., and Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 110 1 (2002) 9-13
3. Horimoto T., and Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3 8 (2005) 591-600
4. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 1 (2003) 192-200
5. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 22 (2005) 2943-2952
6. Horimoto T., Takada A., Fujii K., Goto H., Hatta M., Watanabe S., et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24 17 (2006) 3669-3676
7. Fodor E., Devenish L., Engelhardt O.G., Palese P., Brownlee G.G., and Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 73 11 (1999) 9679-9682
8. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96 16 (1999) 9345-9350
9. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 9-10 (1998) 960-968
10. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493-497
11. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5 3 (1977) 237-247
12. Govorkova E.A., Murti G., Meignier B., de Taisne C., and Webster R.G. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 70 8 (1996) 5519-5524
13. World Health Organisation. WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines (2005), World Health Organization
14. World Health Organisation. Evolution of H5N1 Avian Influenza viruses in Asia. Emerg Inf Dis 11 10 (2005) 1515-1521
15. World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines, 2006 (http://www.who.int/csr/disease/avian_influenza/guidelines/).
16. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 13-14 (2001) 1732-1737
17. Lu X., Tumpey T.M., Morken T., Zaki S.R., Cox N.J., and Katz J.M. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73 7 (1999) 5903-5911
18. Plotkin S.A., Murdin A., and Vidor E. Inactivated polio vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. third ed. (1999), W. B. Saunders, Philadelphia 345-363
19. Stephenson I. H5N1 vaccines: how prepared are we for a pandemic?. Lancet 368 9540 (2006) 965-966
20. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza a (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 9540 (2006) 991-997
21. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
22. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
23. Guan Y., Poon L.L., Cheung C.Y., Ellis T.M., Lim W., Lipatov A.S., et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 101 21 (2004) 8156-8161
24. Horimoto T., Fukuda N., Iwatsuki-Horimoto K., Guan Y., Lim W., Peiris M., et al. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci 66 3 (2004) 303-305
25. Mase M., Tsukamoto K., Imada T., Imai K., Tanimura N., Nakamura K., et al. Characterization of H5N1 influenza A viruses isolated during the 2003-2004 influenza outbreaks in Japan. Virology 332 1 (2005) 167-176
26. Kilbourne E.D., and Arden N.H. Inactivated influenza vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. third ed. (1999), W. B. Saunders, Philadelphia 531-551
27. Doherty P.C., Turner S.J., Webby R.G., and Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 7 5 (2006) 449-455
28. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 10 (2006) 6333-6339
29. Nicholson K.G., Tyrrell D.A., Harrison P., Potter C.W., Jennings R., Clark A., et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7 2 (1979) 123-136
30. McMichael A.J., Gotch F., Cullen P., Askonas B., and Webster R.G. The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 43 2 (1981) 276-284
31. Thomas P.G., Keating R., Hulse-Post D.J., and Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 12 1 (2006) 48-54
32. Lipatov A.S., Webby R.J., Govorkova E.A., Krauss S., and Webster R.G. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 191 8 (2005) 1216-1220
33. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., and Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194 2 (2006) 159-167
34. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated Influenza A H5N1 Candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 9 (2006)